Aging and life span

Advances in Experimental Medicine and Biology

Volumn 567, Issue , 2005, Pages 259-283

  Brown Borg, Holly M ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Body size; Dwarf; Glucose regulation; Longevity; Stress resistance; Therapy; Transgenic

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN;

AGING; BODY SIZE; CLINICAL FEATURE; DRUG MECHANISM; GROWTH HORMONE DEFICIENCY; HORMONAL REGULATION; HORMONE ACTION; HUMAN; LIFESPAN; LONGEVITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STRESS; UNSPECIFIED SIDE EFFECT; ANIMAL; PHYSIOLOGY;

AGING; ANIMALS; GROWTH HORMONE; HUMANS; LONGEVITY; SOMATOMEDINS;

EID: 33644809321     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-26274-1_11     Document Type: Review

References (183)

1. E. Corpas, S.M. Harman and M.R. Blackman, Human growth hormone and human aging. Endocrine Rev, 14, 20-39 (1993).
2. C.V. DeGennaro, M. Zoli, D. Cocchi, A. Maggi, P. Marrama and L.F. Agnati, Reduced growth hormone releasing factor (GHRF)-like immunoreactivity and GHRF gene expression in the hypothalamus of aged rats. Peptides 10, 705-708 (1989).
3. C.V. Degennaro, V. Colonna, F. Fidone, D. Cocchi and E.E. Muller, Feedback effects of growth hormone on growth hormone-releasing hormone and somatostatin are not evident in aged rats. Neurobiol Aging, 14, 503-507 (1993).
4. D. Rudman, M.H. Kutner, C.M. Rogers, M.F. Lubin, G.A. Fleming and R.P. Bain, Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest 67, 1361-1369 (1981).
5. D. Rudman, A.G. Felle, H.S. Nagraj, G.A. Gergans, P.Y. Lalitha, A.F. Goldberg, R.A. Schenkler, L. Cohn, I.W. Rudman and D.E. Mattson. Effects of human growth hormone in men over 60 years old. New Engl J Med, 323, 1-6 (1990).
6. M.A. Papadakis, D. Grady, D. Black, L. Wells and C. Grunfeld, Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med, 124, 708-716 (1996).
7. MW. Sornson, W. Wu, J.S. Dasen, S.E. Flynn, D.J. Norman, S.M. O'Connell, I. Gukovsky, C. Carriere, A.K. Ryan and A.P. Miller, Pituitary lineage determination by the prophet of pit-1 homeodomain factor defective in Ames dwarfism. Nature, 384, 327-333 (1996).
8. V. Chandrashekar and A. Bartke, Induction of endogenous insulin-like growth factor-I secretion alters the hypothalamic-pituitary-testicular function in growth hormone-deficient adult dwarf mice. Biol Repro, 48, 544-551 (1993).
9. H.M. Brown-Borg, K.E. Borg, C.J. Meliska and A. Bartke, Dwarf mice and the aging process. Nature, 384, 33 (1996).
10. K. Flurkey, J. Papconstantinou, R.A. Miller and D.A. Harrison, Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc Natl Acad Sci, 98, 6736-6741 (2001).
11. Y. Zhou, B.C. Xu, H.G. Maheshwari, L. He, M. Reed, M. Lozykowski, S. Okada, T.E. Wagner, L.A. Cataldo, K. Coschigano, G. Baumann and J.J. Kopchick, A mammalian model of Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (The Laron mouse). Proc Natl Acad Sci 94, 13215-13220 (1997).
12. K.T. Coschigano, D. Clemmons, L.L. Bellush and J.J. Kopchick, Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology, 141, 2608-2613 (2000).
13. A. Bartke, V. Chandrashekar, F. Dominici, D. Turyn, B. Kinney, R. Steger and J.J. Kopchick, Insulin-like growth factor-1 (IGF-1) and aging: controversies and new insights. Biogerontology, 4, 1-8 (2003).
14. E.M. Eicher and W.G. Beamer, Inherited ateliotic dwarfism in mice. Characteristics of the mutation, little, on chromosome 6. J Hered 67, 87-91 (1976).
15. P. Godfrey, J. Rahal, W. Beamer, N.G. Copeland, N.A. Jenkins and K.E. Mayo, GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat Genet, 199, 227-232 (1993).
16. S.C. Lin, C.R. Lin, I. Gukovsky, D.M. Simmons, L.W. Swanson and M.G. Rosenfeld, Molecular basis of the little mouse phenotype and implications for cell type specific growth. Nature, 364, 208-213 (1993).
17. W.Y. Chen, D.C. Wight, B.V. Metha, T.E. Wagner and J.J. Kopchick, Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol Endocrinol, 5, 1845-1852 (1991).
18. J.P. Liu, J. Baker, A.S. Perkins, E.J. Robertson and A. Efstratiadis, Mice carrying null mutations of the genes encoding insulin-like growth factor 1 (Igf-1) and type 1 IGF receptor (Igf1r). Cell, 75, 59-72 (1993).
19. L. Powell-Braxton, P. Hollingshead, C. Warburton, M. Dowd, S. Pitts-Meek, D. Dalton, H. Gillett and T.A. Stewart, IGF-1 is required for normal embryonic growth in mice. Genes Dev, 7, 2609-2617 (1996).
20. J.L. Liu and D. LeRoith, Insulin-like growth factor 1 is essential for postnatal growth in response to growth hormone. Endocrinology, 140, 5178-5184 (2001).
21. M. Holzenberger, J. Dupont, B. Ducos, P. Leneuve, A. Geloen, P.C. Even, P. Cervera and Y. Le Bouc, IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature, 421, 182-187 (2003).
22. S. Yakar, J.L. Liu, B. Stannard, A. Butler, D. Accili, B. Sauer and D. LeRoith, Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA, 96, 7324-7329 (1999).
23. S. Yakar, J.L. Liu, A.M. Fernandez, Y. Wu, A.V. Schally, J. Frystyk, S.D. Chernausek, W. Mejia and D. LeRoith, Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes, 50, 1110-1118 (2001).
24. C. Krzisnik, Z. Kolacio, T. Battelino, M. Brown, J.S. Parks and Z. Laron, The 'little people' of the Island of Krk - revisited. Etiology of hypopituitarism revealed. J Endo Genet, 1, 9-19 (1999).
25. D.J. Davenport, Power to the people. Sci Aging Knowledge Environ, 50, ns8 (2003).
26. rd, M. Bala and J. Klassen, The natural history of familial hypopituitarism. Am J Med Genet, 22, 553-566 (1985).
27. A.L. Rosenbloom, J. Guevara-Aguirre, R.G. Rosenfeld and U. Francke, Growth hormone receptor deficiency in Ecuador. J Clin Endocrinol Metab, 84, 4436-4443 (1999).
28. J.A. Barreto-Filho, M.R. Alcantara, R. Salvatori, M.A. Barreto, A.C. Sousa, V. Bastos, A.H. Souza, R.M. Pereira, P.E. Clayton, M.S. Gill and M.H. Aguiar-Oliveira, Familial isolated growth hormone deficiency is associated with increase systolic blood pressure, central obesity and dyslipidemia. J Clin Endocrinol Metab, 87, 2018-2023 (2002).
29. Z. Laron, Natural history of the classical form of primary growth hormone (GH) resistance (Laron syndrome). J Pediatr Endocrinol Metab, 12, 231-249 (1999).
30. J.H. Kranzler, A.L. Rosenbloom, V. Martinez and J. Guevara-Aguirre, Normal intelligence with severe insulin-like growth factor I deficiency due to growth hormone receptor deficiency: a controlled study in a genetically homogeneous population. J Clin Endocrinol Metab, 83, 1953-1958 (1998).
31. B.A. Bengtsson, G. Johannsson, S.M. Shalet, H. Simpson and P.H. Sonken, Treatment of growth hormone deficiency in adults. J Clin Endocrinol Metab, 85, 933-942 (2000).
32. P. Fabrizio, F. Pozza, S.D. Pletcher, C.M. Gendron and V.D. Longo, Regulation of longevity and stress resistance by Sch9 in yeast. Science, 292, 288-290 (2001).
33. K.D. Kimura, H.A. Tissenbaum, Y. Liu and G. Ruvkun, daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science, 277, 942-946 (1997).
34. D. Gems, A.J. Sutton, M.L. Sundermeyer, P.S. Albert, K.V. King, M.L. Edgley, P.L. Larsen and D.L. Riddle, Two pleiotropic classes of daf-2 mutation affect larval arrest, adult behavior, reproduction and longevity in Caenorhabditis elegans. Genetics, 150, 120-155 (1998).
35. L. Guarente and C. Kenyon, Genetic pathways that regulate ageing in model organisms. Nature, 408, 255-262 (2000).
36. A. Dillin, A.L. Hsu, N. Arantes-Oliveira, J. Lehrer-Graiwer, H. Hsin, A.G. Fraser, R.S. Kamath, J. Ahringer and C. Kenyon, Rates of behavior and aging specified by mitochondrial function during development. Science, 298, 2398-2401 (2000).
37. C.A. Wolkow, K.D. Kimura, M.-S. Lee and G. Ruvkun, Regulation of C. elegans life-span by insulinlike signaling in the nervous system. Science, 290, 147-150 (2000).
38. M. Tatar, A. Kopelman, D. Epstein, M.P. Tu, C.M. Yin and R.S. Garofalo, A mutant drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science, 292, 107-110 (2001).
39. D.J. Clancy, D. Gems, L.G. Harshman, S. Oldham, H. Stocker, E. Hafen, S.J. Leevers and L. Partridge, Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science, 292, 104-106 (2001).
40. M. Tatar, N. Priest and S. Chien, Negligible senescence during reproductive diapause in D. melanogaster. Am Nat, 158, 248-258 (2001).
41. W.S. Herman and M. Tatar, Juvenile hormone regulation of longevity in the migratory monarch butterfly. Proc R Soc Land, 268, 2509-2514 (2001).
42. H. Dingle and R. Winchell, Juvenile hormone as a mediator of plasticity in insect life history. Arch Insect Biochem Physiol, 35, 359-373 (1997).
43. W.R. Pendergrass, Y. Li, D. Jiang and N.S. Wolf, Decrease in cellular replicative potential in giant mice transfected with the bovine growth hormone gene correlates to shortened life span. J Cell Physiol, 156, 96-103 (1993).
44. E. Wolf, E. Kahnt, J. Ehrlein, W. Hermanns, G. Brem and R. Wanke, Effects of longterm elevated serum levels of growth hormone on life expectancy of mice: lessons from transgenic animals models. Mech Ageing Dev, 68, 71-87 (1993).
45. M. Cecim, A. Bartke, Y.S. Yun and T.E. Wagner, Expression of human, but not bovine growth hormone genes promotes development of mammary tumors in transgenic mice. Transgenics, 1, 431-437 (1994).
46. L.J. Kajiura and C.D. Rollo, A mass budget for transgenic "supermice" engineered with extra rat growth hormone genes: evidence for energetic limitation. Can J Zool, 72, 1010-1017 (1994).
47. A. Balbis, J.M. Dellacha, R.S. Calandra, A. Bartke and D. Turyn, Down regulation of masked and unmasked insulin receptors in the liver of transgenic mice expressing bovine growth hormone gene. Life Sci, 51, 771-778 (1992).
48. A. Balbis, A. Bartke and D. Turyn, Overexpression of bovine growth hormone in transgenic mice is associated with changes in hepatic insulin receptors and in their kinase activity. Life Sci, 59, 1362-1371 (1996).
49. H.M. Brown-Borg, A.M. Bode and A. Bartke, Antioxidative mechanisms and plasma growth hormone levels: Potential relationship in the aging process. Endocrine, 11, 41-48 (1999).
50. H.M. Brown-Borg and S.G Rakoczy, Catalase expression in delayed and premature aging mouse models. Exp Gerontol, 35, 199-212 (2000).
51. S. Hauck and A. Bartke, Free radical defenses in the liver and kidney of human growth hormone transgenic mice: possible mechanisms of early mortality. J Gerontol Bio Sci, 56A, B153-162 (2001).
52. C.D. Rollo, J. Carlson and M. Sawada, Accelerated aging of giant transgenic mice is associated with elevated free radical processes. Can J Zool, 74, 606-620 (1996).
53. M. Cecim, C. Fadden, J. Kerr, R. Steger and A. Bartke, Infertility in transgenic mice overexpressing the bovine growth hormone gene: disruption of the neuroendocrine control of prolactin secretion during pregnancy. Biol Repro, 52, 1187-1192 (1995).
54. A. Bartke, A.G. Amador, C.J. Meliska, J.S. Yun and T.E. Wagner, Neuroendocrine function, sexual behavior and fertility in transgenic mice expressing growth hormone genes. In: Current Advances in Andrology, G.M.H. Waites, J. Frick and G.W.H. Baker, eds., Proceedings of the VIth International Congress of Andrology, Salzburg, pp. 295-301 (1997).
55. C.D. Rollo, J. Rintoul and L.J. Kajiura, Lifetime reproduction of giant transgenic mice: the energetic stress paradigm. Can J Zool, 78, 1336-1345 (1997).
56. D.B. Miller, A. Bartke and J.P. O'Callaghan, Increased glial fibrillary acidic protein (GFAP) levels in the brains of transgenic mice expressing the bovine growth hormone (bGH) gene. Exp Gerontol, 30, 383-400 (1995).
57. C.J. Meliska, P.A. Burke, A. Bartke and R.A. Jensen, Inhibitory avoidance and appetitive learning in aged normal mice: comparison with transgenic mice having elevated plasma growth hormone levels. Neurobiol Learn Mem, 68, 1-12 (1997).
58. M. Cecim, P.K. Ghosh, A.I. Esquifino, T. Began, T.E. Wagner, J.S. Yun and A. Bartke, Elevated corticosterone levels in transgenic mice expressing human or bovine growth hormone genes. Neuroendocrinology, 53, 313-316 (1991).
59. R. Wanke, E. Wolf, W. Hermanns, S. Folger, T. Buchmuller and G. Brem, The GH-transgenic mouse as an experimental model for growth research: clinical and pathological studies. Horm Res, 37, 74-87 (1992).
60. C.W. Yang, L.J. Striker, C. Pesce, W.Y. Chen, E.P. Paten, S. Elliot, T. Doi, J.J. Kopchick and G.E. Striker, Glomerulosclerosis and body growth are mediated by different portions of bovine growth hormone: studies in transgenic mice. Lab Invest, 68, 62-70 (1993).
61. K.E. Mayo, R.E. Hammer, L.W. Swanson, R.L. Brinster, M.G. Rosenfeld and R.M. Evans, Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone releasing factor gene. Mol Endocrinol, 2, 606-612 (1988).
62. A. Bartke, H.M. Brown-Borg, A.M. Bode, J. Carlson, W.S. Hunter and R.T. Bronson, Does growth hormone prevent or accelerate aging? Exp Gerontol, 33, 675-687 (1998).
63. I. Shimokawa, Y. Higami, M. Utsuyama, T. Tuchiya, T. Komatsu, T. Chiba and H. Yamaza, Life span extension by reduction in growth hormone-insulin-like growth factor-1 axis in a transgenic rat model. Am J Pathology, 160, 2259-2265 (2002).
64. S. Zaina, L. Pettersson, A.B. Thomsen, C.-M. Chai, Z. Qi, J. Thyberg and J. Nilsson, Shortened life span, bradycardia, and hypotension in mice with targeted expression of an Igf2 transgene in smooth muscle cells. Endocrinology, 144, 2695-2703 (2003).
65. M.D. Groesbeck, A.F. Parlow and W.H. Daughaday, Stimulation of supranormal growth in pubertal, adult plateaued, and hypophysectomized female rats by large doses of rat growth hormone: physiological effects and adverse consequences. Endocrinology, 120, 1963-1975 (1987).
66. D.N. Khansari and T. Gustad, Effects of long-term, low-dose growth hormone therapy on immune function and life expectancy of mice. Mech Ageing Dev, 57, 87-100 (1991).
67. D.N. Kalu, P.B. Orhii, C. Chen, D.Y. Lee, G.B. Hubbard, S. Lee and Y. Olatunjibello, Aged-rodent models of long-term growth hormone therapy - lack of deleterious effect on longevity. J Gerontol Biol Sci Med Sci, 53, B452-B463 (1998).
68. L. Sacca, A. Cittadini and S. Fazio, Growth hormone and the heart. Endocrine Rev, 15, 555-573 (1994).
69. A. Colao, A. Balzano, D. Ferone, N. Panza, G. Grande, P. Marzullo, A. Bove, G. Iodice, B. Merola and G. Lombardi, Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clin Endocrinol, 47, 23-28 (1997).
70. P.J. Jenkins, P.D. Fairclough, T. Richards, D.G. Lowe, J. Monson, A. Grossman, J.A. Wass and M. Besser, Acromegaly, colonic polyps and carcinoma. Clin Endocrinol, 47, 17-22 (1997).
71. S.M. Orme, R.H. McNally, R.A. Cartwright and P.E. Belchetz, Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab, 70, (1998).
72. B.A. Bengtsson, S. Eden, I. Ernest, A. Oden and B. Sjogren, Epidemiology and longterm survival in acromegaly. Acta Med Scand, 223, 327-335 (2000).
73. R.D. Utiger, Treatment of acromegaly, New Engl J Med, 342, 1210-1211 (2000).
74. H. Yu and T. Rohan, Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472-1489 (2000).
75. J.M. Chan, M.J. Stampfer, E. Giovannucci, P.H. Gann, J. Ma, P. Wilkinson, C.H. Hennekens and M. Pollak, Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science, 279, 563-566 (1998).
76. A. Wolk, C.S. Mantzoros, S.O. Andersson, R. Bergstrom, L.B. Signorello, P. Lagiou, H.O. Adami and D. Trichopoulos, Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst, 90, 911-915 (1998).
77. S.E. Hankinson, W.C. Willett, G.A. Colditz, D.J. Hunter, D.S. Michaud, B. Deroo, B. Rosner, F.E. Speizer and M. Pollak, Circulating concentrations of IGF-1 and the risk of breast cancer. Lancet, 351, 1593-1596 (1998).
78. J. Ma, M. Pollack, E. Giovanucci, J.M. Chan, X. Tao, C. Hennekens and M.J. Stampfer, A prospective study of plasma levels of IGF-1, IGFBP-3, and colon cancer risk among men. J Natl Cancer Inst, 91, 620-625 (1999).
79. S.T. Ng, J. Zhou, O.O. Adesanya, J. Wang, D. LeRoith and C.A. Bondy, Growth hormone induces mammary gland hyperplasia in aging primates. Nat Med, 3, 1141-1144 (1997).
80. C.E. Rogler, D. Yang, L. Rossetti, J. Donohoe, E. Alt, C.J. Chang, R. Rosenfeld, K. Neely and R. Hintz, Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 269, 13779-13784 (1994).
81. A.S. Bates, A.J. Evans, P. Jones and R.N. Clayton, Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol (Oxf), 42, 417-423 (1995).
82. P. Maison, B. Balkau, D. Simon, P. Chanson, G. Rosselin and E. Eschwege, Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. British Med J, 316, 1132-1133 (1998).
83. J. Takala, E. Ruokonen, N.R. Webster, M.S. Nielsen, D.F. Zandstra, G. Vundelinckx and C.J. Hinds, Increased mortality associated with growth hormone treatment in critically ill adults. N Eng J Med, 341, 785-792 (1999).
84. A.J. Swerdlow, C.D. Higgins, P. Adlard and M.A. Preece, Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet, 360, 273-277 (2002).
85. C.E. Finch and G. Ruvkun, The genetics of aging. Ann Rev Genom Hum Genet, 2, 435-462 (2001).
86. G.J. Patronek, D.J. Waters and L.T. Glickman, Comparative longevity of pet dogs and humans: Implications for gerontology research. J Gerontol, 52A, B171-178 (1997).
87. T.T. Samaras, H. Elrick and L.H. Storms, Is height related to longevity? Life Sci, 72, 1781-1802 (2003).
88. R.C. Roberts, The lifetime growth and reproduction of selected strains of mice. Heredity, 16, 369-381 (1961).
89. P.H. Duffy, R.J. Feuers and R.W. Hart, Effect of chronic caloric restriction on the circadian regulation of physiological and behavioral variable in old male B6C3F1 mice. Chronobiol Int 7:291-303 (1990).
90. C.D. Rollo, Growth negatively impacts life span of mammals. Evol Develop, 55, 55-61 (2002).
91. R.H. Burdon, Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med, 18, 775-794 (1995).
92. H.M. Lander, An essential role for free radicals and derived species in signal transduction. FASEB J, 11, 118-124 (1997).
93. G.N. Rao, K.A. Katki, N.R. Madamanchi, Y. Wu and M.J. Birrer, JunB forms the majority of AP-1 complex and is a target for redox regulation by receptor tyrosine kinase and G protein-coupled receptor agonist in smooth muscle cells. J Biol Chem, 274, 6003-6010 (1999).
94. M.L. Heiman, F.C. Tinsley, J.A. Mattison, S. Hauck and A. Bartke, Body composition of prolactin-, growth hormone, and thyrotropin-deficient Ames dwarf mice. Endocrine, 20, 149-154 (2003).
95. F.P. Dominici, A. Balbis, A. Bartke and D. Turyn, Role of hyperinsulinemia on hepatic insulin binding and insulin receptor autophosphorylation in the presence of high growth hormone (GH) levels in transgenic mice expressing GH gene. J Endocrinol, 159, 1-25 (1998).
96. K.E. Borg, H.M. Brown-Borg and A. Bartke, Assessment of the primary adrenal cortical and pancreatic hormone basal levels in relation to plasma glucose and age in the unstressed Ames dwarf mouse. Proc Soc Biol Med, 210, 126-133 (1995).
97. F.P. Dominici, G. Arostegui Diaz, A. Bartke, J.J. Kopchick and D. Turyn, Compensatory alterations of insulin signal transduction in liver of growth hormone receptor knockout mice. J Endocrinol, 166, 579-590 (2000).
98. F.P. Dominici, D.P. Argentino, A. Bartke and D. Turyn, The dwarf mutation decreases high dose insulin responses in skeletal muscle, the opposite of effects in liver. Mech Ageing Dev, 124, 819-827 (2003).
99. S. Hauck, W.S. Hunter, N. Danilovich, J.J. Kopchick, A. Bartke, Reduced levels of thyroid hormones, insulin and glucose, and lower body core temperature in the growth hormone receptor/binding protein knockout mouse. Exp Biol Med, 226, 552-558 (2001).
100. K.T. Coschigano, M.E. Riders, L.L. Bellush and J.J. Kopchick, Glucose metabolism in growth hormone receptor/binding protein gene disrupted mice. Endocrine Soc Ann Mtg, San Diego, CA, abstract P3-537, p. 553 (1999).
101. J.A. Parsons, A. Bartke and R.L. Sorenson, Number and size of islets of Langerhans in pregnant, human growth hormone-expressing transgenic, and pituitary dwarf mice: effect of lactogenic hormones. Endocrinology, 136, 2013-2021 (1995).
102. C.M. McCay, M. Crowell and L. Maynard, The effect of retarded growth upon the length of life and upon ultimate size. J Nutrition, 10, 63-79 (1935).
103. C.M. McCay, G. Sperling, and L.L. Barnes, Growth, aging, chronic diseases and lifespan in rats, Arch. Biochem. Biophys. 2:469-479 (1947).
104. R. Weindruch and R.L. Walford, Dietary restriction in mice beginning at 1 year of age: effect on life-span and spontaneous cancer incidence. Science, 215, 1415-1418 (1982).
105. R. Weindruch and R.L. Walford, The Retardation of Aging and Disease by Dietary Restriction, Charles C. Thomas, Springfield, IL (1988).
106. T. Chapman and L. Partridge, Female fitness in Drosophila melanogaster: an interaction between the effect of nutrition and of encounter rate with males. Proc R Soc Lond Ser B, 263, 755-759 (1996).
107. M.A. Lane, D.J. Baer, W.V. Rumpler, R. Weindruch, D.K. Ingram, E.M. Tilmont, R.G. Cutler and G.S. Roth, Calorie restriction lowers body temperature in rhesus monkeys, consistent with a postulated anti-aging mechanism in rodents. Proc Natl Acad Sci USA, 93, 4159-4164 (1996).
108. R. Yu, S. Yakar, Y.L. Liu, Y. Lu, D. LeRoith, D. Miao and J.L. Liu, Liver-specific IGF-1 gene deficient mice exhibit accelerated diabetes in response to streptozotocin, associate with early onset of insulin resistance. Mol Cell Endocrinol, 204, 31-42 (2003).
109. K.M. Reiser, Nonenzymatic glycation of collagen in aging and diabetes. Soc Exp Biol Med Minireview, pp. 23-34 (1998).
110. J.W. Baynes and V.M. Monnier, The Maillard Reaction in Aging, Diabetes and Nutrition. Alan R. Liss, New York (1989).
111. F.S. Facchini, N. Hua, F. Abbasi and G.M. Reaven, Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab, 86, 3574-3578 (2001).
112. N. Barzilai, S. Banerjee, M. Hawkins, W. Chen and L. Rossetti, Caloric restriction reverses hepatic insulin resistance in aging rats by decreasing visceral fat. J Clin Invest, 201, 1353-1361 (1998).
113. N. Barzilai and G. Gupta, Revisiting the role of fat mass in the life extension induced by caloric restriction. J Gerontol Biol Sci, 54, B89-B96 (1999).
114. M. Bluher, M.D Michael, O.D. Peroni, K. Ueki, N. Carter, B.B. Kahn and C.R. Kahn, Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell, 3, 25-38 (2002).
115. M. Bluher, B.B. Kahn and C.R. Kahn, Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299, 572-574 (2003).
116. G. Paolisso, A. Gambardella, S. Ammendola, A. D'Amore, V. Balbi, M. Varricchio and F. D'Onofrio, Glucose tolerance and insulin action in healthy centenarians. Am J Physiol, 270, E890-E894 (1996).
117. G. Paolisso, M. Barbieri, M. R. Rizzo, C. Carella, M. Rotondi, M. Bonafe, C. Franceschi, G. Rose and G. De Benedictis, Low insulin resistance and preserved beta-cell function contribute to human longevity but are not associated with TH-INS genes. Exp Gerontol, 37, 149-156 (2001).
118. M. Bonafe, M. Barbieri, F. Marchegiani, F. Olivieri, E. Ragno, C. Giampieri, E. Mugianesi, M. Centurelli, C. Franceschi, and G. Paolisso, Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. J Clin Endocrinol Metab, 88, 3299-3304 (2003).
119. A.W. van den Beld, W.F. Blum, H.A. Pols, D.E. Grobbee and S.W. Lamberts, Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men. Eur J Endocrinol, 148, 627-634 (2003).
120. A. Bartke, Delayed aging in Ames dwarf mice. Relationships to endocrine function and body size. In: Results and Problems in Cell Differentiation: The Molecular Genetics of Aging, S. Hekimi, ed, Vol 29. Springer-Verlag, Berlin, pp. 181-202 (2000).
121. R. Weindruch and S.S. Sohal, Caloric intake and aging. N Engl J Med, 337, 986-994 (1997).
122. J. Meites, Anti-aging interventions and their neuroendocrine aspects in mammals, In: Neurobiology and Neuroendocrinology of Ageing, R. Falvo, A. Bartke, E. Giacobini, eds., Cambridge, J Reprod Fert, pp. 1-9 (1993).
123. A.M. Holehan and B.J. Merry, The control of puberty in dietary restricted female rat. Mech Ageing Dev, 32, 179-191 (1985).
124. J.R. Carey, P. Liedo, L. Harshan, Y. Zhang, H.G. Muller, L. Partridge and J.L. Wang, Life history response of Mediterranean fruit flies to dietary restriction. Aging Cell, 1, 140-148 (2002).
125. M. Tatar, A. Bartke and A. Antebi, The endocrine regulation of aging by insulin-like signals. Science, 299, 1346-1351 (2003).
126. B. Gerisch, C. Weitzel, C. Kober-Eisermann, V. Rottiers and A. Antebi, A hormonal signaling pathway influencing C. elegans metabolism, reproductive development, and life span. Dev Cell, 1, 841-851 (2001).
127. K. Jia, P.S. Albert and D.L. Riddle, DAF-9, a cytochrome P450 regulating C. elegans larval development and adult longevity. Development, 129, 221-231 (2002).
128. H. Hsin and C. Kenyon, Signals from the reproductive system regulate the lifespan of C. elegans. Nature, 399, 362-366 (1999).
129. E.M. Naar, A. Bartke, S.S. Majumdar, F.C. Buonomo, J.S. Yun and T.E. Wagner, Fertility of transgenic female mice expressing bovine growth hormone or human growth hormone variant genes. Biol Reprod, 45, 178-187 (1991).
130. A. Bartke, M. Cecim, K. Tang, R.W. Steger, V. Chandrashekar and D. Turyn, Neuroendocrine and reproductive consequences of overexpression of growth hormone in transgenic mice. Proc Soc Exp Biol Med, 206, 345-359 (1994).
131. V. Chandrashekar, A. Bartke and T.E. Wagner, Endogenous human growth hormone (GH) modulates the effect of gonadotropin-releasing hormone on pituitary function and the gonadotropin response to the negative feedback effect of testosterone in adult transgenic mice bearing human GH gene. Endocrinology, 123, 2717-2722 (1988).
132. D. Harman, Aging. A theory based on free radical and radiation chemistry. J Gerontology, 11, 298-300 (1956).
133. D. Harman, Free radicals in aging. Mol Cell Biochem, 84, 155-161 (1988).
134. H.M. Brown-Borg, S.G. Rakoczy, M.A. Romanick and M.A. Kennedy, Effects of growth hormone and insulin like growth factor-1 on hepatocyte antioxidative enzymes. Exp Biol Med, 227, 94-104 (2002).
135. S. Hauck and A. Bartke, Effects of growth hormone on hypothalamic catalase and CuZn superoxide dismutase. Free Rad Biol Med, 28, 970-978 (2000).
136. M.A. Romanick, S.G. Rakoczy and H.M. Brown-Borg, Long-lived Ames dwarf mouse exhibits increased antioxidant defense in skeletal muscle. Mech Ageing Dev, 125, 269-81 (2004).
137. H.M. Brown-Borg and S.G. Rakoczy, Growth hormone administration to long-living dwarf mice alters multiple components of the antioxidative defense system. Mech Ageing Dev, 124, 1013-1024 (2003).
138. M.M. Meyer, J.C. Swinscoe, H.M. Brown-Borg and E.C. Carlson, Increased glomerular metallothioncin accompanies reduced glomerular basement membrane thickening in the Ames dwarf mouse model of delayed aging, Experimental Biology, San Diego, CA, Abstract # 217.1 (2003).
139. rd Annual Meeting of the Endocrine Society, p. 237 (2001).
140. M. Meyer, R. Schreck, J.M. Muller and P.A. Baeuerle, Redox control of gene expression by eukaryotic transcription factors NF-6B, AP-1, and SRF/TCF. In: Oxidative Stress, Cell Activation and Viral Infection, C. Pasquier, R. Y. Olivier, C. Auclair and L. Packer, Birkhauser Verlag, Basel, pp. 217-235 (1994).
141. F.P. Dominici, D. Cifone, A. Bartke and D. Turyn, Alterations in the early steps of the insulin-signaling system in skeletal muscle of GH-transgenic mice. Am J Physiol, 277, E447-454 (1999).
142. T. Parr, Insulin exposure and unifying aging. Gerontology, 45, 121-135 (1999).
143. A.S. Blair, E. Hajduch, G.J. Litherland and H.S. Hundal, Regulation of glucose transport and glycogen synthesis in L6 muscle cells during oxidative stress. J Biol Chem, 274, 36293-36299 (1999).
144. 2. J Biol Chem, 274, 36293-36299 (1999).
145. A. Tirosh, R. Potashnik, N. Bashan and A. Rudich, Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor sustrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J Biol Chem, 274, 10595-10602 (1999).
146. shc adaptor protein controls oxidative stress response and life span in mammals. Nature, 402, 309-313 (1999).
147. H.M. Brown-Borg, W.T. Johnson, S.G. Rakoczy, M.A. Kennedy and M.A. Romanick, Mitochondrial oxidant production and oxidative damage in Ames dwarf mice. J Am Aging Assoc, 24, 85-96 (2001).
148. A. Sanz, A. Bartke and G. Barja, Long-lived Ames dwarf mice: Oxidative damage to mitochondrial DNA in heart and brain. J Amer Aging Assoc, 25, 119-122 (2002).
149. J.R. Vanfleteren, Oxidative stress and ageing in Caenorhabditis elegans. Biochec J, 292, 605-608 (1993).
150. P.L. Larsen, Aging and resistance to oxidative damage in Caenorhabditis elegans. Proc Natl Acad Sci USA, 90, 8905-8909 (1993).
151. J.R. Vanfleteren and A. De Vreese, The gerontogenes age-1 and daf-2 determine metabolic rate potential in aging Caenorhabditis elegans. FASEB J, 9, 1355-1361 (1995).
152. H. Adachi, Y. Fujiwara and N. Ishii, Effects of oxygen on protein carbonyl and aging in Caenorhabditis elegans mutants with long (age-1) and short (mev-1) life spans. J Gerontol Biol Sci, 53, B240-B244 (1998).
153. Y. Honda and S. Honda, The daf-2 gene network for longevity regulates oxidative stress resistance and MN-superoxide dismutase gene expression in Caenorhabditis elegans. FASEB J, 13, 1385-1393 (1999).
154. P. Fabrizio, L.L. Liou, V.N. Moy, A. Diaspro, J. Selverstone Valentine, E.B. Gralla and V.D. Longo, SOD2 functions downstream of Sch9 to extend longevity in yeast. Genetics, 163, 35-46 (2003).
155. F. Bielschowsky and M. Bielschowsky, Carcinogenesis in the pituitary of dwarf mouse. The response to dimethylbenzanthracene applied to the skin. Br J Cancer, 15, 257-262 (1961).
156. M.M. Ramsey, R.L. Ingram, A.B. Cashion, A.H. Ng, J.M. Cline, A.F. Parlow and W.E. Sonntag, Growth hormone-deficient dwarf animals are resistant to dimethylbenzanthracine (DMBA)-induced mammary carcinogenesis. Endocrinology, 143, 4139-4142 (2002).
157. H.W. Chen, H. Meier, H.-J. Heininger and R.J. Huebner, Tumorigenesis in strain DW/J mice and induction by prolactin of the group-specific antigen of endogenous C-type RNA tumor virus. J Natl Cancer Inst, 49, 1145-1154 (1972).
158. E.G. Rennels, D.M. Anigstein and L. Anigstein, A cumulative study of the growth of sarcoma 180 in anterior pituitary dwarf mice. Tex Rep Biol Med, 23, 776-781 (1965).
159. Y. Ikeno, R.T. Bronson, G.B. Hubbard, S. Lee, A. Bartke, Delayed occurrence of fatal neoplastic diseases in Ames dwarf mice: correlation to extended longevity. J Gerontol, 58A, 291-296 (2003).
160. Yang, 1996,
161. R. Silberberg, Articular aging and osteoarthritis in dwarf mice. Pathologia et Microbiologia, 38, 417-430 (1972).
162. S.M. Jazwinski, Longevity, genes and aging. Science, 273, 54 (1996).
163. G.M. Martin, S.N. Austad and T.E. Johnson, Genetic analysis of ageing: role of oxidative damage and environmental stresses. Nat Genetic, 13, 25-34 (1996,).
164. S. Murakami, A. Salmon and R.A. Miller, Multiplex stress resistance in cells from long-lived dwarf mice. FASEB J, 17, 1565-1566 (2003).
165. K.H. Lange, J.L. Andersen, N. Beyer, F. Isaksson, B. Larsson, M.H. Rasmussen, A. Juul, J. Bulow and M. Kjaer, GH administration changes myosin heavy chain isoforms in skeletal muscle but does not augment muscle strength or hypertrophy, either alone or combined with resistance exercise training in healthy elderly men. J Clin Endocrinol Metab, 87, 513-523 (2002).
166. M.R. Blackman, J.D. Sorkin, T. Munzer, M.F. Bellantoni, J. Busby-Whitehead, T.E. Stevens, J. Jayme, K.G. O'Conner, C. Christmas, J.D. Tobin, K.J. Stewart, E. Cottrell, C. St. Clair, K.M. Pabst and S.M. Harman, Growth hormone and sex steroid administration in health aged women and men. J Am Med Assoc, 288, 2282-2292 ().
167. K. von Werder, The somatopause is no indication for growth hormone therapy. J Endocrinol Invest, 22(Suppl 5), 137-141 (1999).
168. A.A. Toogood and S.M. Shalet, Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study. J Clin Endocrinol Metab, 84, B1-B6 (1999).
169. A.R. Hoffman, S.A. Lieberman and G.P. Ceda, Growth hormone therapy in the elderly: implications for the aging brain. Psychoneuroendocrinology, 17, 327-333 (1992).
170. A. Aleman, H.J.J. de Vries, E.H.F. de Haan, H.J.J. Verhaar, M.M. Samson and H.P. Koppeschaar, Age-sensitive cognitive function, growth hormone and insulin-like growth factor 1 plasma levels in healthy older men. Neuropsychobiology, 41, 73-78 (2000).
171. W.E. Sonntag, C. Lynch, P. Thornton, A. Kahn, S. Bennett and R. Ingram, The effects of growth hormone and IGF-1 deficiency on cerebrovascular and brain aging. J Anat, 197, 575-585 (2000).
172. A.L. Markowska, M. Mooney and W.E. Sonntag, Insulin-like growth factor-1 (IGF-1) ameliorates age-related behavioral deficit. Neuroscience, 87, 559-569 (1998).
173. L.M. Garcia-Segura, G.P. Cardona-Gomez, J.A. Chowen and I. Azcoitia, Insulin-like growth factor-1 receptors and estrogen receptors interact in the promotion of neuronal survival and neuroprotection. J Neurocytol, 29, 425-437 (2000).
174. L.M. Frago, C. Paneda, S.K. Dickson, A.K. Hewson, J. Argente and J.A. Chowen, Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-1 expression and activate intracellular signaling pathways involved in neuroprotection, Endocrinology, 143, 4113-4122 (2002).
175. E. Carro, J.L. Trejo, S. Busiguina and I. Torres-Aleman, Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J Neurosci, 21, 5678-5684 (2001).
176. S. Schneider-Rivas, S. Rivas-Arancibia, F. Vazquez-Pereyra, R. Vazquez-Sandoval and G. Borgonio-Perez, Modulation of long-term memory and extinction responses induced by growth hormone (GH) and growth hormone releasing hormone (GHRH) in rats. Life Sci, 56, PL433-441 (1995).
177. B.A. Kinney, C.J. Meliska, R.W. Steger and A. Bartke, Evidence that Ames dwarf mice age differently from their normal siblings in behavioral and learning and memory parameters. Horm Behav, 39, 277-285 (2001).
178. B.A. Kinney, K.T. Coschigano, J.J. Kopchick, R.W. Steger and A. Bartke, Evidence that age-induced decline in memory retention is delayed in growth hormone resistant GH-R-KO (Laron) mice. Physiol Behav, 72, 653-660 (2001).
179. R.W. Steger, A. Bartke and M. Cecim, Premature ageing in transgenic mice expressing different growth hormone genes. J Reprod Fertil, 46(Supple), 61-75 (1993).
180. M.A. Hynes, J.J. van Wyk, P.J. Brooks, A.J. D'Ercole, M. Jansen and P.K. Lund, Growth hormone dependence of somatomedin-c/insulin-like growth factor I and insulin-like growth factor II messenger ribonucleic acids. Mol Endocrinol, 1, 233-242 (1987).
181. W.E. Sonntag, J.K. Brunso-Bechtold and D.R. Riddle, Age-related decreases in growth hormone and insulin-like growth factor (IGF-1): Implications for brain aging. 4, 311-329 (2001).
182. P.S. van Dam and A. Aleman, Insulin-like growth factor-I, cognition and brain aging. Eur J Pharmacol, 490, 87-95 (2004).
183. E.O. Reiter and R.G. Rosenfeld, Normal and aberrant growth, In: Williams Textbook of Endocrinology, P.R. Larsen, H.M. Kronenberg, S. Melmed and K.S. Polonsky, eds., Tenth Edition, Saunders, Philadelphia, pp. 1003-1114 (2003).